{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:42:18Z","timestamp":1790692938469,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ejmech.2018.04.059","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T01:03:00Z","timestamp":1525136580000},"page":"393-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"special_numbering":"C","title":["New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-1425","authenticated-orcid":false,"given":"Syed Lal","family":"Badshah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.04.059_bib1","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib2","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1073\/pnas.1008678107","article-title":"Escherichia coli condensin MukB stimulates topoisomerase IV activity by a direct physical interaction","volume":"107","author":"Li","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.04.059_bib3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1017\/S003358350800468X","article-title":"DNA topoisomerases: harnessing and constraining energy to govern chromosome topology","volume":"41","author":"Schoeffler","year":"2008","journal-title":"Q.\u00a0Rev. Biophys."},{"key":"10.1016\/j.ejmech.2018.04.059_bib4","series-title":"New Weapons to Control Bacterial Growth","author":"Villa","year":"2016"},{"key":"10.1016\/j.ejmech.2018.04.059_bib5","series-title":"Cytoskeleton Proteins Involved in Chromosome Segregation and Cell Division in Corynebacterium Glutamicum","author":"Donovan","year":"2012"},{"key":"10.1016\/j.ejmech.2018.04.059_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2018.04.059_bib7","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1021\/cb400592n","article-title":"Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug\u2013enzyme interactions","volume":"8","author":"Aldred","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib8","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1073\/pnas.1525055113","article-title":"Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: enhancing drug activity against wild-type and resistant gyrase","author":"Aldred","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.ejmech.2018.04.059_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3390\/molecules21040268","article-title":"The current case of quinolones: synthetic approaches and antibacterial activity","volume":"21","author":"Naeem","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.04.059_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21040268","article-title":"The current case of quinolones: synthetic approaches and antibacterial activity","volume":"21","author":"Naeem","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.04.059_bib11","article-title":"ChemInform abstract: the current case of quinolones: synthetic approaches and antibacterial activity","volume":"47","author":"Naeem","year":"2016","journal-title":"Chem. Inform"},{"key":"10.1016\/j.ejmech.2018.04.059_bib12","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025320","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","volume":"6","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.ejmech.2018.04.059_bib13","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nsmb.1604","article-title":"Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases","volume":"16","author":"Laponogov","year":"2009","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nsmb.1892","article-title":"Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance","volume":"17","author":"Wohlkonig","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00013542-200307000-00003","article-title":"Fluoroquinolone-resistant Streptococcus pneumoniae","volume":"14","author":"D","year":"2003","journal-title":"Rev. Med. Microbiol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcla.21961","article-title":"Rapid detection of genomic mutations in gyrA and parC genes of Escherichia coli by multiplex allele specific polymerase chain reaction","volume":"30","author":"Onseedaeng","year":"2016","journal-title":"J.\u00a0Clin. Lab. Anal."},{"key":"10.1016\/j.ejmech.2018.04.059_bib17","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1128\/AAC.03734-14","article-title":"Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge","volume":"58","author":"Aldred","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/bi501073v","article-title":"Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions","volume":"54","author":"Aldred","year":"2015","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2018.04.059_bib19","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1128\/AAC.45.12.3517-3523.2001","article-title":"Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae","volume":"45","author":"Weigel","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib20","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.4155\/fmc-2016-0042","article-title":"Targeting bacterial topoisomerases: how to counter mechanisms of resistance","volume":"8","author":"Tse-Dinh","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib21","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/cr4003984","article-title":"Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism","volume":"114","author":"Mayer","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2018.04.059_bib22","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1126\/science.aad5196","article-title":"Grelon, A DNA topoisomerase VI\u2013like complex initiates meiotic recombination","volume":"351","author":"Vrielynck","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.04.059_bib23","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.bmcl.2016.03.106","article-title":"Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases","volume":"26","author":"Miles","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib24","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1093\/nar\/gkt124","article-title":"Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance","volume":"41","author":"Aldred","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.04.059_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coph.2014.09.007","article-title":"Novel compounds targeting bacterial DNA topoisomerase\/DNA gyrase","volume":"18","author":"Ehmann","year":"2014","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib26","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In\u00a0vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib27","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1128\/AAC.00527-16","article-title":"Multicenter investigation of gepotidacin (GSK2140944) agar dilution quality control determinations for Neisseria gonorrhoeae ATCC 49226","volume":"60","author":"Jones","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00115-16","article-title":"Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against gram-positive organisms using data from murine infection models","author":"Bulik","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/ml500069w","article-title":"Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents","volume":"5","author":"Singh","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.04.059_bib30","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1016\/j.bmcl.2015.06.061","article-title":"Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5)","volume":"25","author":"Singh","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00619-16","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the novel oxabicyclooctane-linked bacterial topoisomerase inhibitor (NTBI) AM-8722: a selective, potent inhibitor of bacterial DNA gyrase","author":"Tan","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib32","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1128\/AAC.03913-14","article-title":"Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs","volume":"59","author":"Blanco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib33","first-page":"719","article-title":"53RD annual interscience conference on antimicrobial agents and chemotherapy (icaac)","volume":"38","author":"E","year":"2013","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2018.04.059_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12104-015-9652-9","article-title":"Backbone assignment of the N-terminal 24-kDa fragment of Escherichia coli topoisomerase IV ParE subunit","volume":"10","author":"Li","year":"2016","journal-title":"Biomol. NMR Assign"},{"key":"10.1016\/j.ejmech.2018.04.059_bib35","doi-asserted-by":"crossref","first-page":"17743","DOI":"10.1074\/jbc.M116.737429","article-title":"Escherichia coli topoisomerase IV e subunit and an inhibitor binding mode revealed by NMR spectroscopy","volume":"291","author":"Li","year":"2016","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib36","first-page":"1","article-title":"Topoisomerase inhibitors: fluoroquinolone mechanisms of action and resistance","author":"Hooper","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"10.1016\/j.ejmech.2018.04.059_bib37","article-title":"DNA topoisomerase I and DNA gyrase as targets for TB therapy","author":"Nagaraja","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.04.059_bib38","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1093\/nar\/gkw161","article-title":"Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones","volume":"44","author":"Malik","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2018.04.059_bib39","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.jmb.2015.03.019","article-title":"SimC7 is a novel NAD(P)H-dependent ketoreductase essential for the antibiotic activity of the DNA gyrase inhibitor simocyclinone","volume":"427","author":"Sch\u00e4fer","year":"2015","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib40","doi-asserted-by":"crossref","first-page":"10048","DOI":"10.1038\/ncomms10048","article-title":"Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin","volume":"6","author":"Chan","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.04.059_bib41","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1021\/acs.jmedchem.5b00863","article-title":"Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-Linked oxazolidinone substituents leading to a clinical candidate (ETX0914)","volume":"58","author":"Basarab","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1128\/AAC.04124-14","article-title":"In\u00a0vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase\/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria","volume":"59","author":"Huband","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib43","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1128\/AAC.01211-15","article-title":"Multidrug-resistant Neisseria gonorrhoeae isolates from Nanjing, China, are sensitive to killing by a novel DNA gyrase inhibitor, ETX0914 (AZD0914)","volume":"60","author":"Su","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib44","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1128\/AAC.46.5.1174-1182.2002","article-title":"Biosynthetic gene cluster of simocyclinone, a natural multihybrid antibiotic","volume":"46","author":"Trefzer","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib45","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1021\/acschembio.5b00669","article-title":"New simocyclinones: surprising evolutionary and biosynthetic insights","volume":"11","author":"Bilyk","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib46","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/j.jmb.2014.02.017","article-title":"A\u00a0new crystal structure of the bifunctional antibiotic simocyclinone D8 bound to DNA gyrase gives fresh insight into the mechanism of inhibition","volume":"426","author":"Hearnshaw","year":"2014","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib47","doi-asserted-by":"crossref","first-page":"5874","DOI":"10.1016\/j.bmcl.2013.08.094","article-title":"Flavone-based analogues inspired by the natural product simocyclinone D8 as DNA gyrase inhibitors","volume":"23","author":"Verghese","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1128\/AAC.49.3.1093-1100.2005","article-title":"Simocyclinone D8, an inhibitor of DNA gyrase with a novel mode of action","volume":"49","author":"Flatman","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib49","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.1179123","article-title":"A\u00a0crystal structure of the bifunctional antibiotic simocyclinone D8, bound to DNA gyrase","volume":"326","author":"Edwards","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2018.04.059_bib50","doi-asserted-by":"crossref","first-page":"680","DOI":"10.2174\/156802608784221514","article-title":"Glycosyltransferases, important tools for drug design","volume":"8","author":"Luzhetskyy","year":"2008","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkw228","article-title":"In\u00a0vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases","author":"Charrier","year":"2016","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib52","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1016\/j.bmcl.2016.07.061","article-title":"Discovery and structure\u2013activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors","volume":"26","author":"Cooper","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib53","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/1087057113487208","article-title":"Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay","volume":"18","author":"Cunningham","year":"2013","journal-title":"J.\u00a0Biomol. Screen"},{"key":"10.1016\/j.ejmech.2018.04.059_bib54","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1093\/jac\/dkw061","article-title":"Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV","volume":"71","author":"Savage","year":"2016","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib55","doi-asserted-by":"crossref","first-page":"00913","DOI":"10.1128\/AAC.00913-16","article-title":"Efficacy of a novel tricyclic topoisomerase inhibitor in a murine model of Neisseria gonorrhoeae infection, antimicrob","volume":"60","author":"Savage","year":"2016","journal-title":"Agents Chemother"},{"key":"10.1016\/j.ejmech.2018.04.059_bib56","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1128\/AAC.00288-16","article-title":"Small-molecule inhibitors targeting topoisomerase I as novel antituberculosis agents","volume":"60","author":"Sandhaus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib57","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1016\/j.bmc.2016.04.043","article-title":"Discovery and development of kibdelomycin, a new class of broad-spectrum antibiotics targeting the clinically proven bacterial type II topoisomerase","volume":"24","author":"Singh","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib58","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1021\/cb5001197","article-title":"Structures of kibdelomycin bound to Staphylococcus aureus GyrB and ParE showed a novel U-shaped binding mode","volume":"9","author":"Lu","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib59","first-page":"2297","article-title":"Biological and docking studies of topoisomerase IV inhibition by thiosemicarbazides","author":"Siwek","year":"2011","journal-title":"In: J. Mol. Model."},{"key":"10.1016\/j.ejmech.2018.04.059_bib60","first-page":"1","article-title":"Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors","volume":"0","author":"Paneth","year":"2016","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib61","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/jac\/dkl556","article-title":"Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I","volume":"59","author":"Cheng","year":"2007","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2018.04.059_bib62","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4155\/fmc.14.157","article-title":"Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics","volume":"7","author":"Tse-Dinh","year":"2015","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejmech.2010.11.010","article-title":"Synthesis and antimicrobial activity of thiosemicarbazides, s-triazoles and their Mannich bases bearing 3-chlorophenyl moiety","volume":"46","author":"Plech","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib64","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejmech.2014.10.076","article-title":"Mannich bases in medicinal chemistry and drug design","volume":"89","author":"Roman","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib65","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/ardp.19823150406","article-title":"Synthesis of some new thiosemicarbazides, thiadiazoles, triazoles and their derivatives as potential antiviral agents","volume":"315","author":"Bahadur","year":"1982","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2018.04.059_bib66","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.meegid.2016.11.019","article-title":"Analysis of mutations in DNA gyrase and topoisomerase IV of Ureaplasma urealyticum and Ureaplasma parvum serovars resistant to fluoroquinolones","volume":"47","author":"Piccinelli","year":"2017","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib67","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bmc.2016.10.038","article-title":"Design, synthesis and biological evaluation of 4,5-dibromo-N-(thiazol-2-yl)-1H-pyrrole-2-carboxamide derivatives as novel DNA gyrase inhibitors","volume":"25","author":"Toma\u0161i\u010d","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib68","article-title":"Linker-switch approach towards new ATP binding site inhibitors of DNA gyrase B","author":"Juki\u010d","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib69","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2174\/092986707781368414","article-title":"Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents","volume":"14","author":"Oblak","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib70","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bmcl.2016.01.009","article-title":"Fragment-based discovery of DNA gyrase inhibitors targeting the ATPase subunit of GyrB","volume":"26","author":"Mesleh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib71","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00018-010-0299-5","article-title":"In front of and behind the replication fork: bacterial type IIA topoisomerases","volume":"67","author":"Sissi","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.04.059_bib72","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1042\/BST0331460","article-title":"Coupling ATP hydrolysis to DNA strand passage in type IIA DNA topoisomerases","volume":"33","author":"Maxwell","year":"2005","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.ejmech.2018.04.059_bib73","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.sbi.2012.11.011","article-title":"New insights into DNA-binding by type IIA topoisomerases","volume":"23","author":"Chang","year":"2013","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2018.04.059_bib74","doi-asserted-by":"crossref","first-page":"7416","DOI":"10.1016\/j.bmcl.2011.10.010","article-title":"Pyrrolamide DNA gyrase inhibitors: optimization of antibacterial activity and efficacy","volume":"21","author":"Sherer","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib75","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1021\/acsmedchemlett.5b00266","article-title":"Discovery of indazole derivatives as a novel class of bacterial gyrase B inhibitors","volume":"10","author":"Jing Zhang","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.04.059_bib76","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.bmcl.2009.12.060","article-title":"In silico discovery of 2-amino-4-(2,4-dihydroxyphenyl)thiazoles as novel inhibitors of DNA gyrase B","volume":"20","author":"Brvar","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib77","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.bmcl.2012.11.073","article-title":"Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity","volume":"23","author":"Trzoss","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.04.059_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084409","article-title":"Tricyclic GyrB\/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents","volume":"8","author":"Tari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.04.059_bib79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2174\/1568026613666131113153251","article-title":"Prospects for developing new antibacterials targeting bacterial type IIA Topoisomerases","volume":"14","author":"Tomasic","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib80","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.5b00489","article-title":"Discovery of 4,5,6,7-tetrahydrobenzo[1,2- d ]thiazoles as novel DNA gyrase inhibitors targeting the ATP-binding site","volume":"58","author":"Toma\u0161i\u010d","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib81","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.drudis.2008.11.007","article-title":"Ligand efficiency and fragment-based drug discovery","volume":"14","author":"Bembenek","year":"2009","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2018.04.059_bib82","first-page":"1","article-title":"Introduction to fragment-based drug discovery","volume":"317","author":"Erlanson","year":"2012","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib83","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrd3926","article-title":"Fragment-based lead discovery grows up","volume":"12","author":"Baker","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.04.059_bib84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nchem.217","article-title":"The rise of fragment-based drug discovery","volume":"1","author":"Murray","year":"2009","journal-title":"Nat. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib85","article-title":"Fragment-to-Lead medicinal chemistry publications in 2015","author":"Johnson","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.04.059_bib86","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/acsmedchemlett.5b00368","article-title":"Discovery of pyrazolopyridones as a novel class of gyrase B inhibitors using structure guided design","volume":"7","author":"Cross","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.04.059_bib87","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/cplu.201500197","article-title":"Application of fragment-based drug discovery against DNA gyrase B","volume":"80","author":"Chen","year":"2015","journal-title":"Chempluschem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341830401X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352341830401X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T07:30:31Z","timestamp":1563175831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352341830401X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":87,"alternative-id":["S022352341830401X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.059","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.04.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}